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Background and Purpose  The pathogenesis of mitochondrial disease (MD) involves the 
disruption of cellular energy metabolism, which results from defects in the mitochondrial re-
spiratory chain complex (MRC). We investigated whether infants with MRC I defects showed 
ultrastructural changes in skeletal muscle.
Methods  Twelve infants were enrolled in this study. They were initially evaluated for unex-
plained neurodegenerative symptoms, myopathies, or other progressive multiorgan involve-
ment, and underwent muscle biopsies when MD was suspected. Muscle tissue samples were 
subjected to biochemical enzyme assays and observation by transmission electron microscopy. 
We compared and analyzed the ultrastructure of skeletal muscle tissues obtained from patients 
with and without MRC I defects.
Results  Biochemical enzyme assays confirmed the presence of MRC I defects in 7 of the 12 
patients. Larger mitochondria, lipid droplets, and fused structures between the outer mito-
chondrial membrane and lipid droplets were observed in the skeletal muscles of patients with 
MRC I defects.
Conclusions  Mitochondrial functional defects in MRC I disrupt certain activities related to 
adenosine triphosphate synthesis that produce changes in the skeletal muscle. The ultrastructural 
changes observed in the infants in this study might serve as unique markers for the detection of 
MD.
Key Words   mitochondria, respiratory chain complex, infant, muscle pathology, 
ultrastructure, transmission electron microscopy.
Ultrastructural Changes in Skeletal Muscle of Infants 
with Mitochondrial Respiratory Chain Complex I Defects
INTRODUCTION
Defects in the mitochondrial respiratory chain complex (MRC) can disrupt cellular energy 
metabolism, resulting in mitochondrial disease (MD), which is an inherited metabolic disor-
der.1 MRC defects can influence cellular function in various ways, with the neuromuscular 
system typically being affected.2 Diagnosing MD is a challenge because of its genetic hetero-
geneity, diversity in clinical phenotypes, and the lack of gold-standard diagnostic criteria.3 
The diagnosis involves evaluating clinical symptoms, performing imaging studies and bio-
chemical enzyme assays, and assessing the pathology and molecular biology. MD in infants 
is particularly difficult to diagnose because the presentation usually involves clinical symp-
toms that are either atypical or similar to numerous other diseases.4,5
Muscle biopsy is the most helpful diagnostic procedure for evaluating MD, especially 
when other tests produce normal findings.6,7 While the presence of dramatic crystalline in-
clusions in the mitochondria of skeletal muscle is considered an ultrastructural change char-
acteristic of biopsied skeletal muscle in adults with MD, wide variations in the changes in the 
ultrastructure of mitochondria in infants with MD have been reported, including between 
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organ types and MD classifications.
Since morphological changes in the mitochondria of in-
fants with MD have not been characterized adequately, we in-
vestigated the associated ultrastructural changes in the skele-
tal muscle. 
METhODS
Patients and muscle biopsy 
Twelve infants were enrolled in this study. They were initially 
evaluated for unexplained neurodegenerative symptoms, 
myopathies, or other progressive multiorgan involvement. 
Each patient underwent a biopsy of the quadriceps muscle 
when MD was suspected. Lactic acidosis was defined as an 
increase of more than twice the normal reference value. The 
level of serum creatine kinase was normal in all patients.
Biochemical enzyme assays of muscle tissue confirmed the 
presence of MRC I defects in 7 of the 12 patients. Only sub-
jects confirmed by the assay as MRC I were categorized as 
patients in order to ensure homogeneity of the disease state. 
Mitochondrial enzyme functions were evaluated by analyzing 
the activities of reduced nicotinamide adenine dinucleotide 
(NADH)-coenzyme Q (CoQ) reductase (complex I), succi-
nate-CoQ reductase (complex II), succinate-cytochrome c re-
ductase (complex II and III), cytochrome c reductase (com-
plex III), cytochrome c oxidase (complex IV), oligomycin-
sensitive ATPase (complex V), and citrate synthase. The 
activities of these complexes were assessed in isolated mito-
chondria obtained from muscle tissue using standard spectro-
photometric assays, as described by Rustin et al.8 We defined 
MRC defects as a reduction of the residual enzyme activity to 
below 10% of that in controls. The seven patients with MRC I 
defects also satisfied the definitive diagnostic criteria described 
by Bernier et al.9 Five of the original 12 patients did not ex-
hibit defects in biochemical enzyme assays and did not satis-
fy the criteria for MD, and so were categorized as the control 
group without MD.
Transmission electron microscopy was performed using 
samples from patients with MRC I defects and control pa-
tients without enzymatic defects. The study protocol was ap-
proved by the Institutional Review Board of Yonsei University 
Gangnam Severance Hospital, and written informed consent 
was obtained from the parents or legal guardians of all pa-
tients (IRB No. 3-2010-0190).
Sample preparation for electron microscopy
Samples were fixed in 2.5% glutaraldehyde mixed with 2% 
paraformaldehyde solution (0.1 M cacodylate buffer, pH 7.0) 
for 1 hour and then in 2% osmium tetroxide for 1 hour at 4°C. 
The samples were stained en bloc with 2% uranyl acetate, fol-
lowed by dehydration with a graded acetone series and em-
bedding in low-viscosity medium.
Conventional transmission electron microscopy 
and image analysis
Samples were sectioned at 60 nm using an ultramicrotome 
(MTXL, RMC, Tucson, AZ, USA). The sections were double-
stained with 2% uranyl acetate for 20 minutes and lead citrate 
for 10 minutes, then viewed with the aid of transmission elec-
tron microscopy operating at 120 kV (Tecnai 12, FEI, Nether-
lands; H-7600, Hitachi, Tokyo, Japan). 
The total number of intermyofibrillar mitochondria per 
100 µm2 was counted in each group. The concentration of in-
termyofibrillar mitochondria was also checked in each pa-
tient with and without MRC I defects. Every sample was 
photographed within a randomly selected grid square. The 
total counts of mitochondria were divided by the total mea-
sured area in order to calculate the number of mitochondria 
per square micron. Finally, the mitochondria density was ex-
pressed as the mean number of mitochondria per 100 µm2. 
Statistical analysis was performed using Student’s t-test. 
The sizes of 50 randomly chosen mitochondria and lipid 
droplets were measured in each patient using the Image J 
program (National Institutes of Health). Mitochondria and 
lipid droplets were circled, and their actual size was calculated 
using a calibration grid. Values were represented as the mean 
individual size (in square microns) of mitochondria and lipid 
droplets. The statistical significance of differences between 
means was assessed by analysis of variance followed by Student’s 
t-tests. A probability of less than 5% was considered significant 
(p<0.05). Statistical normalization was used to investigate the 
relationship between mitochondria and lipid droplets. 
Three-dimensional structure of lipid droplets and 
mitochondria
For the reconstruction of the three-dimensional (3D) struc-
ture, electron tomography (H-7600) was performed with 
60-nm-thick sections collected on formvar/carbon-coated 
copper slot grids and stained with uranyl acetate and lead ci-
trate. Colloidal gold particles were applied to both sides of 
sections as fiducial markers. A series of 61 tilted images was 
recorded around a tilt axis over an angular range of 120° 
with a tilt interval of 2°. Images were aligned and surface-
rendered models were produced using IMOD (The Mastro-
narde Group, Boulder, CO, USA).10,11 
RESUlTS
Diagnosis of patients 
Central nervous system involvement was observed in all pa-
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tients, with this involving multiple organs in most cases. All 
of the patients showed background slowing in electroen-
cephalograms, which is consistent with encephalopathy, and 
various degrees of involvement in brain magnetic resonance 
imaging (MRI). Patients in both groups (patients with MRC 
I defects and control patients without enzymatic defects) 
showed various clinical characteristics (Table 1 and 2). The 
findings for all enzyme assays other than for MRC I defects 
were normal. One of the patients with MRC I defects was di-
agnosed with Leigh syndrome as a clinical subtype of MD, 
while the other six patients had nonspecific encephalopathy. 
The patient with Leigh syndrome exhibited typical findings 
of lactic acidosis and basal ganglia involvement in brain MRI. 
Light-microscopy examination of the muscle tissues revealed 
no ragged-red fibers. Modified Gomori trichrome and other 
special immunohistochemical staining procedures yielded 
normal results.
MRC I defects, mitochondrial size, and structural 
changes in cristae 
To determine whether MRC I defects caused ultrastructural 
changes, we compared the ultrastructure of skeletal muscle in 
the patients. Enzyme tests revealed that 7 of the 12 originally 
enrolled patients had MRC I defects (Table 1), while the re-
maining 5 patients were included as control individuals for 
comparison. Quantification of these changes showed differ-
ences in mitochondrial size and cristae area between muscles 
with and without MRC I defects (Fig. 1D and E), while there 
were no intergroup differences in mitochondrial numbers 
(Fig. 1F). The mean mitochondrial sizes were 0.21±0.07 and 
0.10±0.03 μm2 in patients with and without MRC I defects, 
respectively (Fig. 1D). Thus, the mitochondria in patients with 
MRC I defects were 53% larger than those in patients without 
such defects (p=0.005) (Fig. 1A-C). In patients with MD, the 
cristae area represented 17.4±3.0% of the total mitochondrial 
area in mitochondria from patients without MRC I defects 
and 7.8±1.8% in mitochondria from patients with these de-
fects, representing a 2.2-fold difference (Fig. 1B, C, and E). 
Moreover, compared with the tubular structure of cristae in 
mitochondria from patients without MD (Fig. 1A), patients 
with MRC I defects exhibited elongated, curved cristae that 
were frequently stacked against one another (Fig. 1B). Other 
obvious structural changes included irregularly shaped mi-
tochondria containing numerous internal vesicles (Fig. 1C). 
MRC I defects and lipid droplets in muscle
A particularly interesting finding was that ultrastructure im-
ages of skeletal muscle showed that the number of intramyo-
cellular lipid droplets (IMCLs) was greater in patients with 
MRC I defects (Fig. 2B and D) than in those without defects Ta
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(Fig. 2A and C). Lipid droplets were frequently observed ad-
jacent to the mitochondria in two-dimensional images (Figs. 
1B and 2D). The size of IMCLs differed significantly (Fig. 
2G), being 0.2127±0.0462 and 0.0647±0.0139 µm2 in pa-
tients with and without MRC I defects, respectively, indicat-
ing a difference of more than threefold (Fig. 2G). Statistical 
normalization was applied to the data to study the relationship 
between structural changes of mitochondria and size increas-
es in lipid droplets in patients. A positive correlation between 
lipid droplet size and mitochondrial size was observed con-
sistently in all of the patients. 
Lipid droplets were surrounded by one or multiple mito-
chondria (Fig. 2D). Electron tomography was applied to im-
prove the resolution of the obtained images and thereby al-
low a more detailed structural analysis of lipid droplets and 
mitochondria. The electron tomograms showed that lipid 
droplets were in direct contact with mitochondria (Fig. 2E), 
and analysis of the 3D structure confirmed that the outer mito-
chondrial membrane was directly connected to the surround-
ing lipid droplets (Fig. 2F).
Table 2. Clinical subtype of MD and brain MRI findings
Patient 
no.
Clinical subtype of MD
Lactic 
acidosis*
Involved area in brain MRI
Basal 
ganglia
Thalamus
Brain 
stem
Cerebellum Cortex
White 
matter
Diffuse 
atrophy
Infarction
1 Nonspecific encephalomyopathy + – – – + + + + –
2 Nonspecific encephalomyopathy + – – – + + + + –
3 Nonspecific encephalomyopathy – – – – – + + + –
4 Leigh syndrome + + + – – – + – –
5 Nonspecific encephalomyopathy + – – – – + + + –
6 Nonspecific encephalomyopathy + – – – – + + – –
7 Nonspecific encephalomyopathy – – – – – – – + –
*More than twofold higher than the normal reference value.
MD: mitochondrial disease, MRI: magnetic resonance imaging.
Fig. 1. Transmission electron microscopy of human mitochondria in skeletal muscle. Mitochondria in muscle without (A) and with (B and C) MRC 
I defects. Mitochondrial size is shown in (D). Changes in the percentage area of cristae and the mitochondrial size are shown in (E). The number of 
mitochondria is counted in (F). The number of mitochondria per square micron was multiplied by 100 to calculate the number of filaments per 100 
μm2. Scale bars indicate 100 nm. MRC: mitochondrial respiratory chain complex.
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DISCUSSION 
Mitochondrial volume homeostasis is a housekeeping cellu-
lar function that helps to regulate oxidative capacity, apopto-
sis, and mechanical signaling. Changes in the mitochondrial 
volume have been shown to be associated with a wide range 
of important biological functions and pathologies. To our 
knowledge, the present study is the first to investigate the mi-
tochondrial size and ultrastructural features of skeletal mus-
cle of infants with MRC I defects. The mitochondrial volume 
is primarily regulated by the potassium flux into and out of 
the matrix, and is controlled by the electrochemical poten-
tial. However, the mitochondrial volume may be altered in 
the presence of various disorders; for example, there are some 
reports of enlarged or swollen mitochondria resulting from 
functional disorders.12-14 An increase in the mitochondrial 
volume has been shown to be related to a reduction in the mi-
tochondrial membrane potential.15 Moreover, an increased 
mitochondrial volume is often observed after mitochondrial 
depolarization, mitochondrial calcium overload, or opening 
of the permeability transition pore.16 Another possible cause 
of mitochondrial swelling is the release of cytochrome c and 
apoptosis-inducing factor.17 
The present study found significant increases in mitochon-
drial size in infants with MRC I defects but no definitive 
changes in the numbers of mitochondria. This finding could 
be due to the significant decrease in cristae. Abundant cristae 
are found in mitochondria from tissues having a high energy 
demand, and so decreases in cristae could be suggestive of 
the presence of functional defects.18,19 The MRC plays a very 
important role in energy production and is mainly localized 
in the inner membrane, particularly within cristae.20,21 Conse-
quently, defects in the MRC could result in structural chang-
es in mitochondria, particularly in cristae that are related to 
the oxidative capacity. When there is a lack of ATP synthase e 
or g subunits22-24 and mitofilin, which is a part of the supramo-
lecular complex of ATP synthase,11,18,25 mitochondria manifest 
as an onion-like structure with decreased cristae and no cristae 
junctions. Enlarged mitochondria have also been observed in 
associated with a reduced cristae area, showing a honeycomb 
structure.26 The present study frequently observed stacked 
cristae with reduced cristae junctions (resembling an onion-
like structure) and interconnected cristae (resembling a hon-
eycomb, vesicle structure) in the mitochondria of patients 
with MRC I defects. These structural changes indicate the 
presence of functional defects and imply that MRC I defects 
may be directly linked to ATP synthase. Furthermore, defects 
in this complex may affect lipid metabolism in mitochondria. 
Such morphological changes in mitochondria have not been 
clearly reported as a tool for differentiating between pediat-
0.3
0.2
0.1
0
MRC 
complex I 
defect
Without MRC 
complex I 
defect
Lipid (μm2)
A  B  C  D  
E  F  G  
Fig. 2. Effects of mitochondrial dysfunction on intramyocellular lipid droplets. These are images from patients without (A and C) and with (B and D) 
MRC I defects. Arrows indicate lipid droplets. Electron tomograms are illustrated in (E). The 3D reconstruction of mitochondria and lipid droplets are 
shown in (F). The outer membrane of the mitochondria is shown in pink and cristae in green. Sizes of lipid droplets were presented as the mean val-
ues for 50 lipid droplets measured in each group (G). Scale bars indicate 5 μm (A and B), 2 μm (C and D), and 100 nm (E). Li: lipid droplet, M: mitochon-
dria, MRC: mitochondrial respiratory chain complex.
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ric and adult MD; however, changes in cristae area and mito-
chondrial size found in the tissues of patients with MRC I 
defects are of clinical importance, particularly in pediatric pa-
tients, and could indicate that MRC I defects are distinct from 
other types of MRC defects. 
The mitochondrial membrane structure is dynamic and 
depends on the ATP level, apoptosis, oxidative stress, and ag-
ing.27-29 Because the membrane dynamics of mitochondria af-
fect mitochondrial function, more detailed analyses of mor-
phological changes in the mitochondria of patients with 
MD have been performed. We applied electron tomography 
in order to improve the imaging resolution,30 which yielded 
detailed images of the mitochondrial structure and direct con-
nections between the mitochondrial outer membrane and lip-
id droplets. Lipid droplets wrapped by mitochondria reflect 
the intimate functional relationship between these two struc-
tures,31 and these results were confirmed by statistical analy-
sis. Statistical normalization suggested the presence of a mu-
tual relationship between the increases in mitochondrial size 
and the number of lipid droplets. ATP is mainly produced by 
mitochondria via the utilization of glucose; however, other 
substances such as glycogen and lipid droplets can also be used 
to produce ATP. When skeletal muscle depends on lipids as 
an energy source, lipid accumulation may result from the 
impaired mitochondrial oxidation of fatty acids.32,33 In addi-
tion, defects in lipid metabolism in mitochondria can affect 
mitochondrial transport to impair energy production, which 
is observed in progressive myopathies.32 
Skeletal muscle is highly reliant on oxidative phosphoryla-
tion. Oxidative metabolism is linked to changes in mitochon-
drial structure and function. Although various changes in mi-
tochondria have been reported in infants with mitochondrial 
dysfunction, no definitive characteristics have been consis-
tently observed. Among the five complexes, MRC I (NADH: 
ubiquinone oxidoreductase) is the largest and most impor-
tant mitochondrial enzyme. MRC I oxidizes NADH from 
the tricarboxylic acid cycle, promotes fatty-acid oxidation and 
glycolysis, reduces ubiquinone during the remaining steps of 
the respiratory chain, and transports protons across the inner 
mitochondrial membrane to support ATP synthesis. Defects 
in MRC I are the main well-known causes of MD.34 However, 
studies of rare diseases such as MD are restricted by the small 
number of affected patients. In the present prospective study, 
we examined fresh biopsies of skeletal muscles in infants with 
or without MRC I defects. Patients were diagnosed based on 
clinical symptoms, the findings of imaging studies and bio-
chemical enzyme assays, and assessing the pathology and mo-
lecular biology. Diagnosing MD in infants is especially diffi-
cult due to atypical clinical presentations and similarities with 
other diseases.4,5 
The present findings suggest that mitochondrial functional 
defects in MRC I can disrupt certain activities related to ATP 
synthesis, resulting in changes in skeletal muscle. Although the 
seven infants with MRC I defects in this prospective study 
might be representative of this unique population, the findings 
cannot be generalized owing to the rarity of the disease. De-
spite this limitation, this study has provided a valuable start-
ing point for clinicians to diagnose MD precisely and under-
stand the natural course of MRC I defects in the pediatric 
population. The ultrastructural changes in mitochondria and 
lipid droplets in infant patients with MRC I defects might be 
useful unique markers for detecting MD.
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